Price dispute blocks costly cancer drug in Canada

June 19, 2006 by  
Filed under CANCER

One of the world’s most costly cancer drugs will not be marketed in Canada because of a price dispute between the drug’s distributor and the federal government.

The colorectal cancer drug Erbitux, which was approved by Health Canada nine months ago, will not be launched after distributor Bristol Myers Squibb Canada could not agree on a price with the federal Patented Medicine Prices Review Board., The Globe and Mail reports.


While Erbitux has not yet been proven to extend the lives of colorectal cancer patients, it does shrink tumours in some patients and delay tumour growth, especially when used as a combination treatment.

MORE: | Price dispute blocks costly cancer drug in Canada

Related Posts with Thumbnails

NOTE: The contents in this blog are for informational purposes only, and should not be construed as medical advice, diagnosis, treatment or a substitute for professional care. Always seek the advice of your physician or other qualified health professional before making changes to any existing treatment or program. Some of the information presented in this blog may already be out of date.